Advanced Proteome Therapeutics Corporation (APTCF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | - USD | -100.0% |
| 2022 | 759.61 Thousand USD | 141.41% |
| 2021 | -1.83 Million USD | -307.1% |
| 2020 | -450.63 Thousand USD | -35.14% |
| 2019 | -333.46 Thousand USD | 55.23% |
| 2018 | -744.77 Thousand USD | -3.19% |
| 2017 | -721.72 Thousand USD | 16.8% |
| 2016 | -867.44 Thousand USD | 2.19% |
| 2015 | -886.86 Thousand USD | 22.88% |
| 2014 | -1.14 Million USD | -12.62% |
| 2013 | -1.02 Million USD | -35.04% |
| 2012 | -756.17 Thousand USD | 30.08% |
| 2011 | -1.08 Million USD | 5.73% |
| 2010 | -1.14 Million USD | -17.77% |
| 2009 | -974.16 Thousand USD | 14.21% |
| 2008 | -1.13 Million USD | 40.11% |
| 2007 | -1.89 Million USD | -162497.77% |
| 2006 | -1166.00 USD | -100.04% |
| 2005 | 2.62 Million USD | 4112.4% |
| 2004 | -65.5 Thousand USD | -101.36% |
| 2003 | 4.81 Million USD | 297.25% |
| 2002 | -2.44 Million USD | 20.31% |
| 2001 | -3.06 Million USD | -52.33% |
| 2000 | -2.01 Million USD | 65.97% |
| 1999 | -5.91 Million USD | -243.92% |
| 1998 | -1.71 Million USD | -171.84% |
| 1997 | 2.39 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | - USD | 0.0% |
| 2023 Q4 | - USD | 100.0% |
| 2023 Q2 | -277.98 Thousand USD | -32.56% |
| 2023 Q1 | -209.71 Thousand USD | -175.37% |
| 2023 FY | - USD | -100.0% |
| 2023 Q3 | -1.47 Million USD | -431.65% |
| 2022 Q2 | 627.77 Thousand USD | -7.11% |
| 2022 FY | 759.61 Thousand USD | 141.41% |
| 2022 Q4 | -76.15 Thousand USD | 83.72% |
| 2022 Q1 | 675.84 Thousand USD | 348.15% |
| 2022 Q3 | -467.84 Thousand USD | -174.53% |
| 2021 FY | -1.83 Million USD | -307.1% |
| 2021 Q1 | -342.23 Thousand USD | -71.85% |
| 2021 Q2 | 27.54 Thousand USD | 108.05% |
| 2021 Q3 | -1.67 Million USD | -6166.12% |
| 2021 Q4 | 150.8 Thousand USD | 109.03% |
| 2020 Q1 | -17.8 Thousand USD | 92.08% |
| 2020 Q3 | -119.84 Thousand USD | -5.28% |
| 2020 FY | -450.63 Thousand USD | -35.14% |
| 2020 Q4 | -199.14 Thousand USD | -66.17% |
| 2020 Q2 | -113.83 Thousand USD | -539.25% |
| 2019 Q2 | 127.46 Thousand USD | 164.56% |
| 2019 FY | -333.46 Thousand USD | 55.23% |
| 2019 Q1 | -197.43 Thousand USD | 49.26% |
| 2019 Q4 | -224.78 Thousand USD | -480.66% |
| 2019 Q3 | -38.71 Thousand USD | -130.37% |
| 2018 Q2 | -639.11 Thousand USD | -335.73% |
| 2018 Q1 | -146.67 Thousand USD | -4.96% |
| 2018 Q4 | -389.12 Thousand USD | -190.46% |
| 2018 FY | -744.77 Thousand USD | -3.19% |
| 2018 Q3 | 430.14 Thousand USD | 167.3% |
| 2017 FY | -721.72 Thousand USD | 16.8% |
| 2017 Q4 | -139.75 Thousand USD | 26.16% |
| 2017 Q3 | -189.26 Thousand USD | 12.75% |
| 2017 Q2 | -216.93 Thousand USD | -23.41% |
| 2017 Q1 | -175.77 Thousand USD | 59.17% |
| 2016 Q2 | -162.84 Thousand USD | -25.49% |
| 2016 Q3 | -144.34 Thousand USD | 11.36% |
| 2016 Q4 | -430.5 Thousand USD | -198.26% |
| 2016 Q1 | -129.76 Thousand USD | 44.28% |
| 2016 FY | -867.44 Thousand USD | 2.19% |
| 2015 Q3 | -311.22 Thousand USD | -45.41% |
| 2015 Q1 | -128.7 Thousand USD | -131.9% |
| 2015 FY | -886.86 Thousand USD | 22.88% |
| 2015 Q2 | -214.03 Thousand USD | -66.3% |
| 2015 Q4 | -232.9 Thousand USD | 25.17% |
| 2014 Q2 | -1.66 Million USD | -2058.27% |
| 2014 Q4 | 403.42 Thousand USD | 112.25% |
| 2014 Q1 | -77.2 Thousand USD | 58.4% |
| 2014 Q3 | 190.07 Thousand USD | 111.41% |
| 2014 FY | -1.14 Million USD | -12.62% |
| 2013 Q1 | -148.82 Thousand USD | 40.04% |
| 2013 Q4 | -185.58 Thousand USD | 54.31% |
| 2013 Q3 | -406.18 Thousand USD | -52.89% |
| 2013 Q2 | -265.67 Thousand USD | -78.51% |
| 2013 FY | -1.02 Million USD | -35.04% |
| 2012 FY | -756.17 Thousand USD | 30.08% |
| 2012 Q1 | -105.54 Thousand USD | 55.81% |
| 2012 Q2 | -158.68 Thousand USD | -50.36% |
| 2012 Q3 | -243.71 Thousand USD | -53.59% |
| 2012 Q4 | -248.23 Thousand USD | -1.85% |
| 2011 Q4 | -238.82 Thousand USD | 21.12% |
| 2011 FY | -1.08 Million USD | 5.73% |
| 2011 Q3 | -302.75 Thousand USD | -9.9% |
| 2011 Q2 | -275.47 Thousand USD | -4.17% |
| 2011 Q1 | -264.44 Thousand USD | -46.17% |
| 2010 Q1 | -413.41 Thousand USD | -47.06% |
| 2010 Q3 | -264.35 Thousand USD | 8.38% |
| 2010 Q4 | -180.91 Thousand USD | 31.56% |
| 2010 FY | -1.14 Million USD | -17.77% |
| 2010 Q2 | -288.54 Thousand USD | 30.21% |
| 2009 Q2 | -204.24 Thousand USD | 20.85% |
| 2009 FY | -974.16 Thousand USD | 14.21% |
| 2009 Q3 | -230.72 Thousand USD | -12.97% |
| 2009 Q4 | -281.12 Thousand USD | -21.84% |
| 2009 Q1 | -258.04 Thousand USD | 15.22% |
| 2008 Q4 | -304.36 Thousand USD | -16.92% |
| 2008 Q1 | -314.26 Thousand USD | 76.13% |
| 2008 Q3 | -260.32 Thousand USD | 27.53% |
| 2008 Q2 | -359.24 Thousand USD | -14.31% |
| 2008 FY | -1.13 Million USD | 40.11% |
| 2007 Q2 | -113.25 Thousand USD | -52.18% |
| 2007 Q1 | -74.42 Thousand USD | -183.43% |
| 2007 FY | -1.89 Million USD | -162497.77% |
| 2007 Q4 | -1.31 Million USD | -236.33% |
| 2007 Q3 | -391.49 Thousand USD | -245.67% |
| 2006 Q4 | 89.2 Thousand USD | 271.1% |
| 2006 Q2 | -52.53 Thousand USD | -633.81% |
| 2006 Q1 | 9841.00 USD | -99.66% |
| 2006 FY | -1166.00 USD | -100.04% |
| 2006 Q3 | -52.13 Thousand USD | 0.75% |
| 2005 Q4 | 2.87 Million USD | 6230.23% |
| 2005 FY | 2.62 Million USD | 4112.4% |
| 2005 Q1 | -51.55 Thousand USD | -134.75% |
| 2005 Q2 | -147.19 Thousand USD | -185.49% |
| 2005 Q3 | -46.88 Thousand USD | 68.15% |
| 2004 Q3 | -43.42 Thousand USD | 71.2% |
| 2004 Q1 | -19.65 Thousand USD | 94.69% |
| 2004 Q4 | 148.35 Thousand USD | 441.6% |
| 2004 FY | -65.5 Thousand USD | -101.36% |
| 2004 Q2 | -150.77 Thousand USD | -667.1% |
| 2003 FY | 4.81 Million USD | 297.25% |
| 2003 Q3 | -201.09 Thousand USD | -103.44% |
| 2003 Q4 | -369.82 Thousand USD | -83.91% |
| 2003 Q1 | -447.74 Thousand USD | 31.8% |
| 2003 Q2 | 5.83 Million USD | 1403.79% |
| 2002 Q3 | -650.42 Thousand USD | 19.54% |
| 2002 Q1 | -328.06 Thousand USD | 76.61% |
| 2002 FY | -2.44 Million USD | 20.31% |
| 2002 Q4 | -656.47 Thousand USD | -0.93% |
| 2002 Q2 | -808.39 Thousand USD | -146.42% |
| 2001 Q1 | -503.37 Thousand USD | 55.64% |
| 2001 FY | -3.06 Million USD | -52.33% |
| 2001 Q4 | -1.4 Million USD | -217.28% |
| 2001 Q3 | -442.07 Thousand USD | 36.2% |
| 2001 Q2 | -692.9 Thousand USD | -37.65% |
| 2000 Q3 | 337.61 Thousand USD | 132.56% |
| 2000 Q1 | -203.9 Thousand USD | 96.1% |
| 2000 FY | -2.01 Million USD | 65.97% |
| 2000 Q2 | -1.03 Million USD | -408.5% |
| 2000 Q4 | -1.13 Million USD | -436.15% |
| 1999 Q4 | -5.22 Million USD | -1171.42% |
| 1999 Q3 | -411.32 Thousand USD | -224.29% |
| 1999 Q2 | 330.95 Thousand USD | 156.75% |
| 1999 Q1 | -583.12 Thousand USD | 0.0% |
| 1999 FY | -5.91 Million USD | -243.92% |
| 1998 Q1 | -497.05 Thousand USD | 0.0% |
| 1998 FY | -1.71 Million USD | -171.84% |
| 1998 Q3 | 698.51 Thousand USD | 439.08% |
| 1998 Q2 | -206 Thousand USD | 58.56% |
| 1998 Q4 | - USD | -100.0% |
| 1997 FY | 2.39 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | 100.0% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 100.0% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 100.0% |
| Nascent Biotech, Inc. | -2.08 Million USD | 100.0% |
| Rebus Holdings, Inc. | -1.02 Million USD | 100.0% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 100.0% |
| Qrons Inc. | -789.34 Thousand USD | 100.0% |
| Adynxx, Inc. | - USD | NaN% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 100.0% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 100.0% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 100.0% |
| Skye Bioscience, Inc. | -37.64 Million USD | 100.0% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 100.0% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 100.0% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | 100.0% |
| SQZ Biotechnologies Company | -79.46 Million USD | 100.0% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 100.0% |
| Propanc Biopharma, Inc. | -1.82 Million USD | 100.0% |
| Mesoblast Limited | -87.95 Million USD | 100.0% |
| Marizyme, Inc. | -65.34 Million USD | 100.0% |
| Genus plc | 7.9 Million USD | 100.0% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 100.0% |
| Pharming Group N.V. | -10.54 Million USD | 100.0% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | 100.0% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 100.0% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 100.0% |
| ContraFect Corporation | -65.15 Million USD | 100.0% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 100.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | NaN% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | 100.0% |
| IMV Inc. | -36.48 Million USD | 100.0% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 100.0% |
| MultiCell Technologies, Inc. | -380.07 USD | 100.0% |
| ONE Bio Corp. | 8.67 Million USD | 100.0% |
| Accustem Sciences Inc. | -3.74 Million USD | 100.0% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 100.0% |
| Arno Therapeutics, Inc. | - USD | NaN% |
| EV Biologics, Inc. | -1.26 Million USD | 100.0% |
| Q BioMed Inc. | -2.05 Million USD | 100.0% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 100.0% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | 100.0% |
| Biomind Labs Inc. | -1.21 Million USD | 100.0% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 100.0% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 100.0% |
| TetraLogic Pharmaceuticals Corporation | - USD | NaN% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 100.0% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | 100.0% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | 100.0% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 100.0% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 100.0% |
| GB Sciences, Inc. | -1.36 Million USD | 100.0% |
| Alpha Cognition Inc. | -13.77 Million USD | 100.0% |
| HST Global, Inc. | -146.21 Thousand USD | 100.0% |
| CSL Limited | 2.64 Billion USD | 100.0% |
| Wesana Health Holdings Inc. | -1.75 Million USD | 100.0% |
| Halberd Corporation | -79.67 Thousand USD | 100.0% |
| Enzolytics Inc. | -2.17 Million USD | 100.0% |
| Agentix Corp. | -1.37 Million USD | 100.0% |
| Resverlogix Corp. | -3.61 Million USD | 100.0% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 100.0% |
| MetaStat, Inc. | - USD | NaN% |
| argenx SE | -295.05 Million USD | 100.0% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 100.0% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 100.0% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 100.0% |
| GeneThera, Inc. | - USD | NaN% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 100.0% |
| AVAX Technologies, Inc. | -6.41 Million USD | 100.0% |
| Zenith Capital Corp. | -10.59 Million USD | 100.0% |
| Genscript Biotech Corporation | -95.47 Million USD | 100.0% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | 100.0% |
| Anthera Pharmaceuticals, Inc. | - USD | NaN% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 100.0% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | 100.0% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 100.0% |
| Kadimastem Ltd | -3.3 Million USD | 100.0% |
| Helix BioMedix, Inc. | -1.05 Million USD | 100.0% |
| VitaSpring Biomedical Co. Ltd. | - USD | NaN% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 100.0% |
| BioStem Technologies, Inc. | -8.48 Million USD | 100.0% |
| Oncology Pharma Inc. | - USD | NaN% |
| Reve Technologies, Inc. | -441.36 Thousand USD | 100.0% |
| LadRx Corporation | 400.44 Thousand USD | 100.0% |
| Cell Source, Inc. | -5.32 Million USD | 100.0% |
| Regen BioPharma, Inc. | 1.02 Million USD | 100.0% |
| Regen BioPharma, Inc. | 1.02 Million USD | 100.0% |
| NovAccess Global Inc. | -4.76 Million USD | 100.0% |
| Affymax, Inc. | -14.42 Million USD | 100.0% |
| Itoco Inc. | -1.86 Million USD | 100.0% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 100.0% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | 100.0% |
| Mobile Lads Corp. | -2.26 Million USD | 100.0% |
| CytoDyn Inc. | -49.84 Million USD | 100.0% |
| Claritas Pharmaceuticals, Inc. | - USD | NaN% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | 100.0% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | 100.0% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | 100.0% |
| SYBLEU INC | -180.3 Thousand USD | 100.0% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | 100.0% |
| International Stem Cell Corporation | -131 Thousand USD | 100.0% |
| Bioxytran, Inc. | -4.28 Million USD | 100.0% |
| GlobeImmune, Inc. | - USD | NaN% |
| Predictive Technology Group, Inc. | - USD | NaN% |
| ProText Mobility, Inc. | -54.27 Thousand USD | 100.0% |
| Cardax, Inc. | - USD | NaN% |
| VG Life Sciences Inc. | -2.53 Million USD | 100.0% |
| Kaleido Biosciences, Inc. | - USD | NaN% |
| Advaxis, Inc. | -48.07 Million USD | 100.0% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | 100.0% |
| RenovaCare, Inc. | - USD | NaN% |
| Regnum Corp. | -780.88 Thousand USD | 100.0% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 100.0% |
| Neutra Corp. | -233.46 Thousand USD | 100.0% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 100.0% |
| PureTech Health plc | -65.69 Million USD | 100.0% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 100.0% |
| IXICO plc | -1.17 Million USD | 100.0% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 100.0% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 100.0% |
| CSL Limited | 2.64 Billion USD | 100.0% |
| Cellectis S.A. | -103.17 Million USD | 100.0% |